<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of" exact="Chikungunya" post="Virus (CHIKV) PuranikNinad V.†§∥RaniRuchi‡∥SinghVedita Anand‡TomarShailly*‡PuntambekarHemalata M.†§SrivastavaPratibha*†§[†], Agharkar Research InstituteIndia[‡],"/>
 <result pre="to nearly 95 and 93% concentration, respectively, in cells with" exact="CHIKV" post="infection. Further, the CHIKV-inhibitory capacity of these compounds was"/>
 <result pre="against prime antiviral entrants, leading to remedial management to preclude" exact="CHIKV" post="infection. Introduction The cases of chikungunya viral fever are"/>
 <result pre="going through joint ache as a result of chikungunya infection." exact="Chikungunya" post="virus (CHIKV) spreads by mosquito vectors Aedes aegypti and"/>
 <result pre="are primates and humans. In humans, the symptoms associated with" exact="CHIKV" post="are nausea, fever, joint pain, vomiting, rashes, and persistent"/>
 <result pre="by positive polymerase chain reaction (PCR) results.3,4 In Togaviridae family," exact="CHIKV" post="comes under the genus Alphavirus. Alphaviruses are configured as"/>
 <result pre="Encapsidated by 240 copies of CP, the RNA genome of" exact="CHIKV" post="makes the nucleocapsid core.13,14 The grown-up alphavirus virion (70"/>
 <result pre="E1 and E2 (surface glycoproteins) heterodimers build up every spike.15" exact="CHIKV" post="bears a genome of almost ∼11.7 kb, polyadenylated at"/>
 <result pre="and the activity of nsP3 mono(ADP-ribosyl)hydrolase is somewhere decisive for" exact="CHIKV" post="replication and virulence in mice. At the N-terminus, nsP3"/>
 <result pre="in the market for the cure of CHIKV-infected patients. Some" exact="CHIKV" post="vaccine approaches have been analyzed, together with inefficient, live"/>
 <result pre="in vitro screening of chloroquine, ribavirin, and arbidol to curb" exact="CHIKV" post="progress have failed to produce noteworthy therapeutic aids in"/>
 <result pre="356 natural product molecules and clinically recommended medicines to counteract" exact="CHIKV" post="replicon, and an accompanying test with the surrogate infection"/>
 <result pre="(SFV),25 during analyses of 3040 small compounds as inhibitors of" exact="CHIKV" post="nsP2, was also tested by the phenotypic assay protocol.26"/>
 <result pre="protocol.26 Still, the problem for the prevention and treatment of" exact="CHIKV" post="fever is recalcitrant. Therefore, it is necessary to work"/>
 <result pre="with the macrodomain of nsP3 and their antiviral potential against" exact="CHIKV" post="are reported. Based on the outcomes of antiviral screening"/>
 <result pre="were conducted to determine the inhibitory potential of compounds on" exact="CHIKV" post="replication, and quantitative real-time polymerase chain reaction (qRT-PCR) was"/>
 <result pre="assay (IFA) was carried out to investigate the reduction in" exact="CHIKV" post="antigen upon treatment with the screened compounds. Results and"/>
 <result pre="molecular understanding of the particular binding of ADP-ribose to the" exact="CHIKV" post="nsP3 macrodomain revealed that nsP3 amino acids Asp 10,"/>
 <result pre="contacts with the amino acid residues of nsP3 in the" exact="CHIKV" post="nsP3–ADP-ribose complex (Figure 2a,b). Figure 2 Molecular docking of"/>
 <result pre="Residues of 3GPO with 5a–f Table 2 Interaction Analysis of" exact="CHIKV" post="nsP3 with ADP-Ribose and Halogenated Dihydrorugosaflavonoids s. no. ADP-ribose"/>
 <result pre="with a dotted line; (c and d) dose-dependent inhibition of" exact="CHIKV" post="shown by 5c and 5d, respectively. 5c and 5d"/>
 <result pre="5c and 5d both exhibit a statistically significant reduction in" exact="CHIKV" post="titer at micromolar concentrations. In the analysis, statistical significance"/>
 <result pre="70 μM concentration. Plaque Reduction Assay The reduction in the" exact="CHIKV" post="infectivity in the presence of 5c and 5d compounds"/>
 <result pre="compounds for CHIKV. Figure 4 Demonstration of antiviral activity against" exact="CHIKV" post="in treated Vero cells. Dihydrorugosaflavonoid-treated Vero cells (pretreated cells)"/>
 <result pre="Vero cells. Dihydrorugosaflavonoid-treated Vero cells (pretreated cells) were infected with" exact="CHIKV" post="at an MOI of 1 for 90 min. Followed"/>
 <result pre="validating the antiviral effect of 5c and 5d by quantifying" exact="CHIKV" post="RNA levels in the infected cells. The reduction in"/>
 <result pre="treated with 5c and 5d compounds at 24 hpi. The" exact="CHIKV" post="RNA levels upon treatment with 70 and 50 μM"/>
 <result pre="5d, with 70 and 50 μM, the RNA levels of" exact="CHIKV" post="were reduced to ∼ 93 and 91%, respectively (Figure"/>
 <result pre="respectively (Figure 5). Figure 5 (a, b) Relative quantification of" exact="CHIKV" post="mRNA of Vero cells treated with 5c and 5d"/>
 <result pre="PCR. Compounds were added to the cells 12 h before" exact="CHIKV" post="infection and were present in the post-infection medium. Viral"/>
 <result pre="antigen in this study for virus detection by IFA. Here," exact="CHIKV" post="at an MOI of 1 was propagated in Vero"/>
 <result pre="6 clearly shows that both 5c and 5d compounds inhibited" exact="CHIKV" post="at 70 and 50 μM concentrations. Figure 6 Evaluation"/>
 <result pre="all over the world to identify the lead molecules restricting" exact="CHIKV" post="infection or replication. In this piece of work, molecular"/>
 <result pre="reduction assay displayed that compounds 5c and 5d potentially inhibit" exact="CHIKV" post="infection. Further, qRT-PCR assay results clearly show the potential"/>
 <result pre="in infected cells. Furthermore, the antiviral activity of dihydrorugosaflavonoids toward" exact="CHIKV" post="is also well delivered by IFA. Conclusions Flavonoid compounds"/>
 <result pre="to the same class and display their potential to inhibit" exact="CHIKV" post="replication. In conclusion, it could be explicated that halogenated"/>
 <result pre="in a 5% CO2 incubator. Using the virus adsorption technique," exact="CHIKV" post="(accession number, KY057363.1; strain, 119067)50 stocks were prepared in"/>
 <result pre="At MOI of 1, the cell monolayer was infected with" exact="CHIKV" post="with gentle shaking after every 15 min for 90"/>
 <result pre="plate to isolate RNA for qRT-PCR. Furthermore, the CPE of" exact="CHIKV" post="on the Vero cell line appeared in ∼48 h"/>
 <result pre="hpi, the cell supernatant was harvested, and the 10-fold serial-diluted" exact="CHIKV" post="supernatant was added to the Vero cells and incubated"/>
 <result pre="4. Table 4 Sequence of Oligonucleotides Used as Primers in" exact="CHIKV" post="Virus in Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) primers"/>
 <result pre="control to screen possible contamination. RNA extracted from the untreated" exact="CHIKV" post="supernatant was used as a positive control. Experiments were"/>
 <result pre="concentrations of 5c and 5d compounds prior to and after" exact="CHIKV" post="infection. At 36 hpi, cells were washed three times"/>
 <result pre="Virol.2014, 88, 11644–11647. 10.1128/JVI.01432-14.25078691 National Vector Borne Disease Control Programme." exact="Chikungunya" post="Fever. http://nvbdcp.gov.in/chikun-status.html (accessed April 2018). ChoiH. K.; LeeS.; ZhangY."/>
 <result pre="DuquerroyS.; VonrheinC.; Girard-BlancC.; CrubletE.; ThompsonA.; BricogneG.; ReyF. A.Glycoprotein organization of" exact="Chikungunya" post="virus particles revealed by X-ray crystallography. Nature2010, 468, 709–712."/>
 <result pre="KistemakereH. A.; FilippovD. V.; GriffinD. E.; LeungA. K.ADP-ribosylhydrolase activity of" exact="Chikungunya" post="virus macrodomain is critical for virus replication and virulence."/>
 <result pre="KamY. W.; OngE. K.; ReniaL.; TongJ. C.; NgL. F.Immuno-biology of" exact="Chikungunya" post="and implications for disease intervention. Microbes. Infect.2009, 11, 1186–1196."/>
 <result pre="10.1086/514240.9498442 BriolantS.; GarinD.; ScaramozzinoN.; JouanA.; CranceJ. M.In vitro inhibition of" exact="Chikungunya" post="and Semliki Forest viruses replication by antiviral compounds: synergistic"/>
 <result pre="PastorinoB.; BarontiC.; NougairedeA.; BonnetE.In vitro antiviral activity of arbidol against" exact="Chikungunya" post="virus and characteristics of a selected resistant mutant. Antiviral"/>
 <result pre="mutant. Antiviral Res.2011, 90, 99–107. 10.1016/j.antiviral.2011.03.182.21440006 RavichandranR.; ManianM.Ribavirin therapy for" exact="Chikungunya" post="arthritis. J. Infect. Dev. Ctries.2008, 2, 140–142. 10.3855/T2.2.140.19738340 PohjalaL.;"/>
 <result pre="MeritsA.Inhibitors of alphavirus entry and replication identified with a stable" exact="Chikungunya" post="replicon cell line and virus-based assays. PLoS One2011, 6,"/>
 <result pre="e2892310.1371/journal.pone.0028923.22205980 Lucas-HouraniM.; LupanA.; DespresP.; ThoretS.; PamlardO.A phenotypic assay to identify" exact="Chikungunya" post="virus inhibitors targeting the nonstructural protein nsP2. J. Biomol."/>
 <result pre="SchwartzO.; HansenM. A. E.; Freitas-JuniorL. H.Identification of Novel Compounds Inhibiting" exact="Chikungunya" post="Virus-Induced Cell Death by High Throughput Screening of a"/>
 <result pre="RossettiG.; LüscherB.; VerheugdP.The conserved macrodomains of the non-structural proteins of" exact="Chikungunya" post="virus and other pathogenic positive strand RNA viruses function"/>
 <result pre="HiggsS.; VanlandinghamD.; BakarS. A.; ZandiK.Antiviral activity of selected flavonoids against" exact="Chikungunya" post="virus. Antiviral Res.2016, 133, 50–61. 10.1016/j.antiviral.2016.07.009.27460167 FrosJ. J.; DomeradzkaN."/>
</results>
